Mundipharma presents positive findings from largest ever flutiform® study and supportive new data on flutiform® k-haler® at ERS 2017

September 12, 2017 at 12:28 PM

Chippenham, UK: Vectura's partner, the Mundipharma network, presented the following data on flutiform® at the European Respiratory Society International Congress ("ERS") 2017: 

  • The largest ever flutiform® study confirms effectiveness and tolerability in real-world clinical practice (AffIRM study)
    • First presentation of largest ever real-world flutiform® study involving over 2,500 patients
    • Safety profile of flutiform pMDI in practice was consistent with that demonstrated in clinical trials
    • Proportion of patients with well-controlled asthma more than doubled 12 months after switching to flutiform® pMDI
  • New data on flutiform® k-haler® (125/5 microgram), Mundipharma's novel breath-triggered aerosol inhaler currently under development, demonstrating efficient drug delivery characteristics
    • flutiform® k-haler® achieved high levels of lung deposition of over 44% of delivered dose
    • Plume force of flutiform® k-haler was compared with fluticasone propionate/salmeterol xinafoate delivered via the Seretide® Evohaler® pMDI and Sirdupla® pMDI devices
    • Pharmacokinetic studies show efficacy and safety profile of new flutiform® k-haler® device would be comparable to flutiform® pMDI device

Further details can be found on the Mundipharma web site as follows:

http://www.mundipharma.com/docs/default-source/press-releases-library/ers-affirm-data-release-final.pdf?sfvrsn=0

http://www.mundipharma.com/docs/default-source/press-releases-library/ers-data-release-100917.pdf?sfvrsn=0 

James Ward-Lilley, Chief Executive Officer of Vectura:
"AffIRM is the largest ever real-world flutiform study, and provides further evidence this is an effective and differentiated treatment for asthma patients. In addition, if approved, flutiform k-haler a breath-triggered inhaler device will provide another option for patients and we look forward to a conclusion of the ongoing regulatory review in Europe in due course." 

- Ends -

Enquiries

Vectura Group plc
Andrew Derodra - Chief Financial Officer
Fleur Wood -  Director Communications
Elizabeth Knowles - Director Investor Relations and Analysis

+44 (0)1249 667 700

Consilium Strategic Communications
Mary-Jane Elliott / Sue Stuart / Jessica Hodgson

+44 (0)20 3709 5700
vectura@consilium-comms.com


About Vectura
Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading device and formulation business for inhaled airways products offering a uniquely integrated inhaled drug delivery platform. With our extensive range of device and formulation technologies, integrated capabilities and collaborations, we are a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases.  

Vectura has eight inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams.  The Group has a diverse portfolio of drugs in clinical development, including a number of novel and generic programmes which are partnered with several global pharmaceutical and biotechnology companies including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Bayer, Chiesi, Almirall, Janssen, Dynavax and Tianjin KingYork along with two wholly owned nebulised development programmes.

Forward-looking statements
This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Vectura's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Tags:
back to top